Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease

Journal of Neuroimmunology

Volumn 266, Issue 1-2, 2014, Pages 1-11

  Matsuo, Kazuhiko ^a,c   Okamoto, Hideaki ^a   Kawai, Yasuaki ^a   Quan, Ying Shu ^b   Kamiyama, Fumio ^b   Hirobe, Sachiko ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b CosMED Pharmaceutical Co Ltd ^*  (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Dissolving microneedle array; Transcutaneous immunization; Vaccine therapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] ANTIBODY; IMMUNOGLOBULIN G; PLACEBO; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; EQUIPMENT DESIGN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; MICRONEEDLE; MINIMALLY INVASIVE PROCEDURE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84891483071     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.11.002     Document Type: Article

References (38)

1. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
2. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
3. Bergstedt-Lindqvist S., Moon H.B., Persson U., Möller G., Heusser C., Severinson E. Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur. J. Immunol. 1988, 18:1073-1077.
4. Blennow K., Zetterberg H., Rinne J.O., Salloway S., Wei J., Black R., Grundman M., Liu E., AAB-001 201/202 Investigators Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 2012, 69:1002-1010.
5. Boeglin E., Smulski C.R., Brun S., Milosevic S., Schneider P., Fournel S. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One 2011, 6:e25542.
6. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
7. Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., DeMattos R.B., Mohs R., Paul S.M., Siemers E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012, 8:261-271.
8. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
9. Finkelman F.D., Katona I.M., Mosmann T.R., Coffman R.L. IFN-γ regulates the isotypes of Ig secreted during in vivo humoral immune responses. J. Immunol. 1988, 140:1022-1027.
10. Fujita H., Asahina A., Sugaya M., Nakamura K., Gao P., Fujiwara H., Tamaki K. Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J. Invest. Dermatol. 2005, 124:343-350.
11. Hara H., Monsonego A., Yuasa K., Adachi K., Xiao X., Takeda S., Takahashi K., Weiner H.L., Tabira T. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. 2004, 6:483-488.
12. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
13. Hirobe S., Azukizawa H., Matsuo K., Zhai Y., Quan Y.S., Kamiyama F., Suzuki H., Katayama I., Okada N., Nakagawa S. Development and Clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm. Res. 2013, 30:2664-2674.
14. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 2002, 8:1270-1275.
15. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
16. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 2007, 27:363-371.
17. Ishii Y., Nakae T., Sakamoto F., Matsuo K., Matsuo K., Quan Y.S., Kamiyama F., Fujita T., Yamamoto A., Nakagawa S., Okada N. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J. Control. Release 2008, 131:113-120.
18. Ishii-Katsuno R., Nakajima A., Katsuno T., Nojima J., Futai E., Sasagawa N., Yoshida T., Watanabe Y., Ishiura S. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination. Biochem. Biophys. Res. Commun. 2010, 399:593-599.
19. Lambracht-Washington D., Qu B.X., Fu M., Eagar T.N., Stüve O., Rosenberg R.N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302:1796-1802.
20. Larregina A.T., Morelli A.E., Spencer L.A., Logar A.J., Watkins S.C., Thomson A.W., Falo L.D. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat. Immunol. 2001, 2:1151-1158.
21. Li Y., Ma Y., Zong L.X., Xing X.N., Sha S., Cao Y.P. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 induces Th2 immune response against amyloid-β in wild-type mouse. Neurosci. Lett. 2011, 505:128-133.
22. Matsuda J., Kaminaka K., Nozaki C. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 2009, 382:149-152.
23. Matsuo K., Ishii Y., Quan Y.S., Kamiyama F., Mukai Y., Yoshioka Y., Okada N., Nakagawa S. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J. Control. Release 2011, 149:15-20.
24. Matsuo K., Hirobe S., Yokota Y., Ayabe Y., Seto M., Quan Y.S., Kamiyama F., Tougan T., Horii T., Mukai Y., Okada N., Nakagawa S. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J. Control. Release 2012, 160:495-501.
25. Matsuo K., Yokota Y., Zhai Y., Quan Y.S., Kamiyama F., Mukai Y., Okada N., Nakagawa S. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J. Control. Release 2012, 161:10-17.
26. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
27. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007, 21:2135-2148.
28. Movsesyan N., Davtyan H., Mkrtichyan M., Petrushina I., Tiraturyan T., Ross T., Agadjanyan M.G., Ghochikyan A., Cribbs D.H. Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum. Gene Ther. 2010, 21:128-133.
29. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
30. Niizeki H., Streilein J.W. Hapten-specific tolerance induced by acute, low-dose ultraviolet B radiation of skin is mediated via interleukin-10. J. Invest. Dermatol. 1997, 109:25-30.
31. Nikolic W.V., Bai Y., Obregon D., Hou H., Mori T., Zeng J., Ehrhart J., Shytle R.D., Giunta B., Morgan D., Town T., Tan J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2507-2512.
32. Nojima J., Maeda A., Aoki S., Suo S., Yanagihara D., Watanabe Y., Yoshida T., Ishiura S. Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model. Vaccine 2011, 29:6252-6258.
33. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
34. Sariol C.A., Martínez M.I., Rivera F., Rodríguez I.V., Pantoja P., Abel K., Arana T., Giavedoni L., Hodara V., White L.J., Angleró Y.I., Montaner L.J., Kraiselburd E.N. Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques. PLoS One 2011, 6:e19323.
35. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
36. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
37. Tada Y., Asahina A., Fujita H., Sugaya M., Tamaki K. Langerhans cells do not produce interferon-γ. J. Invest. Dermatol. 2003, 120:891-892.
38. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., Maguire R.P., Blennow K., Lundmark J., Staufenbiel M., Orgogozo J.M., Graf A. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012, 11:597-604.